Autres langues CARsgen Therapeutics Holdings Limited

Actions

2171

KYG1996C1006

Temps Différé Hong Kong S.E. Autres places de cotation 04:04:30 18/07/2024			Varia. 5j.	Varia. 1 janv.
4,54 ^HKD	+1,11 %		+10,73 %	-30,15 %

27/06	L'actionnaire important de CARsgen Therapeutics augmente sa participation à 37,78%.	MT
15/06	CARsgen Therapeutics Holdings Limited présente les premiers résultats chez l'homme de l'étude CAR-T CT071 ciblant GPRC5D à l'EHA 2024	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

CARsgen Therapeutics' Substantial Shareholder Boosts Stake to 37.78%	27/06
CARsgen Therapeutics Holdings Limited Presents First-In-Human Results of GPRC5D Targeting CAR-T CT071 At EHA 2024	15/06
Carsgen Therapeutics Holdings Limited Provides Updated Research Results on SATRI-CEL in Nature Medicine And At the 2024 Asco Annual Meeting	04/06
CARsgen Therapeutics Holdings Limited commences an Equity Buyback Plan for 57,564,391 shares, representing 10% of its issued share capital, under the authorization approved on May 21, 2024.	31/05
CARsgen Submitted Responses to FDA Observations	30/04
CARsgen Therapeutics Holdings Limited Announces Abstracts from the Ongoing Studies of zevorcabtagene autoleucel and CT071 to be Presented as an Oral Presentation and a Poster Presentation, Respectively, at the Upcoming EHA 2024	30/04
CARsgen Therapeutics Holdings Limited Announces Board and Committee Changes	29/04
CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations	29/04
Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024	12/04
CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma	04/03
CARsgen Therapeutics’ New Drug Application for Multiple Myeloma Drug Gets Approval from Chinese Regulator	01/03
National Medical Products Administration of China Approves New Drug Application of CARsgen Therapeutics Holdings Limited for Zevorcabtagene Autoleucel	01/03
CARsgen Presents Data from Phase 1B Study on Gastric, Gastroesophageal Junction Cancer Drug at US Meet	19/01
Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting	19/01
CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage a hepatocellular carcinoma at high risk of recurrence after surgical resection	16/01
China Grants CARsgen Clinical Trial Clearance for Liver Cancer Treatment; Shares Rise 3%	15/01
CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug Clearance from the National Medical Products Administration	15/01
CARsgen Therapeutics Holdings Shareholder Plans Stake Boost; Shares Fall 6%	18/12
US FDA Puts CARsgen's Three Drug Candidates Under Clinical Hold Following Factory Inspections; Shares Plummet 27%	13/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues CARsgen Therapeutics Holdings Limited

Actions

2171

KYG1996C1006

Autres langues

Filtres